FLT3’s pivotal role in AML cell proliferation and survival, along with its frequent mutation and overexpression in a substantial proportion of AML patients [5, 6], positions FLT3 as an appealing therapeutic target. The gene discussed is FLT3; the disease is acute myeloid leukemia.